DR Reddys Laboratories,inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: DR Reddys Laboratories,inc Pharmaceutical Import Records from India — 6 Products, $9.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

DR Reddys Laboratories,inc — Pharmaceutical Importer Profile (2026) | 6 Products, $9.1M Trade | TransData Nexus

DR Reddys Laboratories,inc

Pharmaceutical Importer · United States · Cardiovascular Focus · $9.1M Total Trade · DGFT Verified

DR Reddys Laboratories,inc is a pharmaceutical importer based in United States with a total trade value of $9.1M across 6 products in 5 therapeutic categories. Based on 189 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. DR Reddys Laboratories,inc sources from 1 verified Indian supplier, with Dr.reddy's Laboratories Limited accounting for 100.0% of imports.

DR Reddys Laboratories,inc — Import Portfolio & Supplier Network

DR Reddys Laboratories,inc import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to DR Reddys Laboratories,inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr.reddy's Laboratories Limited	$28.7M	1,026	100.0%

DR Reddys Laboratories,inc sources from 1 verified Indian supplier across 546 distinct formulations. The sourcing is highly concentrated — Dr.reddy's Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Metoprolol succinate extended-release	$468.6K	10
Omeprazole delayed-release capsules	$438.3K	10
300022792 daptomycin injection	$300.0K	6
300026282 doxorubicin hydrochloride	$250.0K	5
300026772 doxorubicin hydrochloride	$236.8K	5
300022792 daptomycin injection	$200.0K	4
Daptomycin injection 500MG/vial 1s	$200.0K	4
Daptomycin injection 500MG/vial	$150.0K	3
Clopidogrel tablets USP 75MG 500s (14817x 500s packs=7408500 nos	$150.0K	3
Methocarbamol injection,USP 1000MG/10ML(100MG/ML) 10s (8560 x 10s packs=85600 nos	$150.0K	3
Clopidogrel tablets USP 300MG 30s (2448x 30s packs=73440 nos	$150.0K	3
Lamotrigine extended release tablets 200MG 30s (80304 x 30s packs=2409120 nos	$150.0K	3
Clopidogrel tablets USP 75MG 500s (18532x 500s packs=9266000 nos	$150.0K	3
Fondaparinux sod INJ 10MG/0.8ML pfs 10s(4101 x 10s packs=41010 nos	$150.0K	3
Fluoxetine delayed-release capsules usp90mg 4s (total qty packs 8640x4s=34560nos	$150.0K	3

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metoprolol	Cardiovascular	$5.4M	115	0.7%	13
2	Clopidogrel	Cardiovascular	$1.9M	38	0.8%	19
3	Doxorubicin	Oncology	$1.1M	22	1.6%	2
4	Ciprofloxacin	Antibiotics	$300.0K	6	0.1%	14
5	Dexamethasone	Corticosteroids	$300.0K	6	0.2%	10
6	Phenylephrine	Respiratory & OTC	$100.0K	2	0.1%	4

DR Reddys Laboratories,inc imports 6 pharmaceutical products across 5 categories into United States totaling $9.1M.

DR Reddys Laboratories,inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Dr. Reddy's Laboratories, Inc. is a U.S.-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from India. As a subsidiary of Dr. Reddy's Laboratories Limited, headquartered in Hyderabad, India, the company plays a pivotal role in distributing a diverse range of generic medications across the United States. Their portfolio encompasses various therapeutic areas, including cardiovascular, oncology, and antibiotics, reflecting a strategic focus on high-demand segments within the U.S. healthcare market.

In March 2025, Dr. Reddy's Laboratories, Inc. completed the sale of its subsidiary, Dr. Reddy's Laboratories Louisiana LLC, which included a manufacturing facility in Shreveport, Louisiana. This divestiture indicates a strategic realignment, potentially focusing more on distribution and less on domestic manufacturing within the U.S.

2Distribution Network

Dr. Reddy's Laboratories, Inc. operates a comprehensive distribution network across the United States, leveraging its parent company's global manufacturing capabilities. While specific warehouse locations are not publicly disclosed, the company utilizes a combination of centralized and regional distribution centers to ensure efficient delivery of pharmaceutical products nationwide. This logistical framework is designed to meet the diverse needs of the U.S. market, ensuring timely and reliable access to a wide array of medications.

3Industry Role

In the U.S. pharmaceutical supply chain, Dr. Reddy's Laboratories, Inc. functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from India, the company bridges the gap between Indian manufacturers and U.S. healthcare providers, facilitating the availability of generic medications. This role is crucial in enhancing market competition and providing cost-effective alternatives to brand-name drugs, thereby contributing to the overall efficiency and affordability of the U.S. healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — DR Reddys Laboratories,inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Dr. Reddy's Laboratories, Inc. demonstrates a high degree of sourcing concentration, importing 98.9% of its products from a single supplier: Dr. Reddy's Laboratories Limited. This single-source dependency could pose risks related to supply chain disruptions, such as manufacturing delays or quality control issues. However, the consistent volume of 1,026 shipments over the period from 2022 to 2026 suggests a stable and reliable relationship between the importer and the supplier, potentially mitigating some of these risks.

2Supply Chain Resilience

The resilience of Dr. Reddy's Laboratories, Inc.'s supply chain is closely tied to the stability and reliability of Dr. Reddy's Laboratories Limited in India. The company's focus on finished pharmaceutical formulations, with 546 unique formulations imported, indicates a diversified product range that may help buffer against supply chain disruptions. However, the reliance on a single supplier and the potential for geopolitical or logistical challenges in international shipping routes could impact supply chain continuity. Ensuring compliance with U.S. Food and Drug Administration (FDA) regulations is essential for maintaining uninterrupted market access.

3Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation, distribution, and marketing of drugs. For Indian generics, the FDA requires an Abbreviated New Drug Application (ANDA) for approval, ensuring that the generic product is bioequivalent to its brand-name counterpart. This process involves rigorous evaluation of the drug's safety, efficacy, and manufacturing quality.

2Import Licensing & GMP

Import licensing for pharmaceutical products in the U.S. involves registration of foreign drug establishments with the FDA and listing of all drug products intended for import. Manufacturers must comply with Good Manufacturing Practice (GMP) standards, which are recognized by the FDA. While the FDA does not have a formal recognition process for foreign GMP certifications, compliance with FDA regulations is mandatory for all imported drugs. Additionally, wholesale distributors must obtain appropriate licenses to operate within the U.S., ensuring adherence to federal and state regulations.

Quality & Labeling

DR Reddys Laboratories,inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Dr. Reddy's Laboratories, Inc. focuses on importing pharmaceutical products in the cardiovascular, oncology, and antibiotics therapeutic areas. This strategic emphasis aligns with high-demand segments in the U.S. healthcare market, addressing prevalent health conditions and contributing to improved patient outcomes. The company's portfolio includes medications such as metoprolol, clopidogrel, doxorubicin, ciprofloxacin, and dexamethasone, reflecting a commitment to providing essential treatments across these critical therapeutic areas.

2Sourcing Profile

Dr. Reddy's Laboratories, Inc. primarily sources generic drug formulations from its parent company, Dr. Reddy's Laboratories Limited in India. This sourcing strategy leverages the manufacturing capabilities and regulatory compliance of the parent company, ensuring a consistent supply of high-quality pharmaceutical products. The focus on finished pharmaceutical formulations allows the company to offer a diverse range of medications to the U.S. market, catering to various therapeutic needs.

3Market Positioning

By importing a diverse range of generic pharmaceutical products, Dr. Reddy's Laboratories, Inc. serves multiple segments of the U.S. market, including retail pharmacies, hospitals, and wholesale distributors. The company's strategic focus on high-demand therapeutic areas positions it as a key player in providing cost-effective alternatives to brand-name drugs, thereby enhancing access to essential medications across the healthcare system.

Seller's Guide — How to Become a Supplier to DR Reddys Laboratories,inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the U.S. market by meeting FDA regulatory requirements and establishing direct relationships with importers like Dr. Reddy's Laboratories, Inc. Gaps in the current sourcing strategy, such as the reliance on a single supplier, present potential avenues for diversification. By offering high-quality, competitively priced products and ensuring compliance with FDA standards, new suppliers can position themselves as valuable partners in enhancing supply chain resilience and meeting the diverse needs of the U.S. pharmaceutical market.

2Requirements & Qualifications

Indian exporters seeking to supply Dr. Reddy's Laboratories, Inc. and the broader U.S. market must obtain FDA approval for their drug products, typically through the ANDA process. Manufacturers must comply with FDA's GMP standards, which are recognized by the agency. Additionally, products must meet FDA labeling requirements, including truthful and informative labeling in English. Ensuring compliance with these standards is essential for successful market entry and distribution within the United States.

3How to Approach

Frequently Asked Questions — DR Reddys Laboratories,inc

What products does DR Reddys Laboratories,inc import from India?

DR Reddys Laboratories,inc imports 6 pharmaceutical products across 5 categories. Top imports: Metoprolol ($5.4M), Clopidogrel ($1.9M), Doxorubicin ($1.1M), Ciprofloxacin ($300.0K), Dexamethasone ($300.0K).

Who supplies pharmaceuticals to DR Reddys Laboratories,inc from India?

DR Reddys Laboratories,inc sources from 1 verified Indian suppliers. The primary supplier is Dr.reddy's Laboratories Limited (100.0% of imports, $28.7M).

What is DR Reddys Laboratories,inc's total pharmaceutical import value?

DR Reddys Laboratories,inc's total pharmaceutical import value from India is $9.1M, based on 189 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does DR Reddys Laboratories,inc focus on?

DR Reddys Laboratories,inc imports across 5 categories. The largest: Cardiovascular (80.1%), Oncology (12.1%), Antibiotics (3.3%).

Get Full DR Reddys Laboratories,inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.